BioNTech SE (BNTX) gained 6.96% at $325.98 in the premarket at the last check on Friday. In the previous trading session, the stock went down by 1.32% to $304.76 at a volume of 2.39 million. While it fluctuated between $291.85 and $306.82. In the past 52 weeks, the stock has seen a high of $464.00 and a low of $80.55 at an average volume of 3.06 million. The stock has gained 11.20% this week, while it lost 17.63% in the past three months. Overall, BNTX stock has gained a value of 273.85% year to date. Today’s uptrend in the stock is a result of CHMP’s positive opinion for using its Covid-19 vaccine in children 5 to 12 in the EU.
Incorporated in 2008, BioNTech SE (BNTX) is a biotechnology company. It develops and commercializes immunotherapies for cancer and other infectious diseases.
CHMP’s Opinion and Covid Situation
As per the news of November 25, Pfizer and BioNTech both received a positive opinion for Comirnaty® in children 5-12 in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for use of the vaccine in children. Comirnaty® is a protective vaccine against Covid-19 developed by both Pfizer and BioNTech (BNTX). So far the vaccine was only administered in adults, mostly those who were predisposed.
The CHMP’s opinion of the vaccine was based on the scientific data of the vaccines obtained from its various trials. Based on the recommendation of CHMP, the European Commission (EC) will grant the final decision. If accepted, Comirnaty® will be the first Covid-19 vaccine for children 5-12 years in the European Union.
With winters arriving in most areas, Covid-19 seems to be hitting back not only with its delta variant but a new unidentified strain as well. As per the news, a new variant called B.1.1.529 has emerged in Hong Kong. After which, travel restrictions have again started being implemented. With the escalating Covid-19 situation due to changing weather. And the new strains, it has become of utmost importance for vaccines to be issued for children as well.
If accepted, Comirnaty would be a step towards the most unmet need of the protection of children against Covid-19 and its various strains. While it has yet to be determined if the new strain is responsive to the current vaccines at all.